NCT02259127 is a Phase 2, PHASE3 clinical trial of Dolutegravir in HIV Infection, sponsored by PENTA Foundation.

Who is sponsoring NCT02259127?

NCT02259127 is sponsored by PENTA Foundation.

What drugs are being tested in NCT02259127?

Interventions in NCT02259127: Dolutegravir, Standard of Care.

What condition does NCT02259127 study?

NCT02259127 studies HIV Infection.

Is NCT02259127 still recruiting?

NCT02259127 is currently completed. Last updated 29 July 2025.

Are results published for NCT02259127?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-07-29 · How we verify

NCT02259127

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ODYSSEY (PENTA 20)

Completed Phase 2, PHASE3 Results posted Last updated 29 July 2025

What this trial tests

Phase 2, PHASE3 trial testing Dolutegravir in HIV Infection in 792 participants. Completed in 7 December 2023.

Timeline

20 September 2016

Primary endpoint
2 March 2021

7 December 2023

Quick facts

Lead sponsor	PENTA Foundation
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	792
Start date	20 September 2016
Primary completion	2 March 2021
Estimated completion	7 December 2023
Sites	28 locations across Zimbabwe, South Africa, Uganda, United Kingdom, Germany, Thailand, Portugal, Spain

Drugs / interventions tested

Dolutegravir (DOLUTEGRAVIR) — full drug profile →
Standard of Care

Conditions studied

HIV Infection — all drugs for HIV Infection →

Sponsor

PENTA Foundation

Who can join

Adults 28 Days to 18, any sex, with HIV Infection. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Difference in Proportion With Failure (Clinical or Virological) Primary · 96 weeks post randomisation

Treatment failure by 96 weeks. Estimated using time to the first occurrence of any of the following components: * Insufficient virological response defined as \< 1 log10 drop at week 24 and switch to second/third line ART for treatment failure * Viral Load (VL)\>400 c/ml at or after 36 weeks confirmed by next visit * Death due to any cause * Any new or recurrent AIDS defining event (WHO 4) or severe WHO 3 events, adjudicated by the Endpoint Review Committee

Insufficient virological response

Group	Value	95% CI
Dolutegravir (>=14kg Cohort)	0
Standard of Care (>=14kg Cohort)	3
Dolutegravir (<14kg Cohort)	0
Standard of Care (<14kg Cohort)	0
Dolutegravir - ODYSSEY A (>=14kg Cohort)	0
Standard of Care - ODYSSEY A (>=14kg Cohort)	2
Dolutegravir - ODYSSEY B (>=14kg Cohort)	0
Standard of Care - ODYSSEY B (>=14kg Cohort)	1

Confirmed VL>=400 copies/mL

Group	Value	95% CI
Dolutegravir (>=14kg Cohort)	40
Standard of Care (>=14kg Cohort)	64
Dolutegravir (<14kg Cohort)	9
Standard of Care (<14kg Cohort)	16
Dolutegravir - ODYSSEY A (>=14kg Cohort)	10
Standard of Care - ODYSSEY A (>=14kg Cohort)	26
Dolutegravir - ODYSSEY B (>=14kg Cohort)	30
Standard of Care - ODYSSEY B (>=14kg Cohort)	38

Severe WHO 3

Group	Value	95% CI
Dolutegravir (>=14kg Cohort)	0
Standard of Care (>=14kg Cohort)	1
Dolutegravir (<14kg Cohort)	0
Standard of Care (<14kg Cohort)	0
Dolutegravir - ODYSSEY A (>=14kg Cohort)	0
Standard of Care - ODYSSEY A (>=14kg Cohort)	0
Dolutegravir - ODYSSEY B (>=14kg Cohort)	0
Standard of Care - ODYSSEY B (>=14kg Cohort)	1

WHO 4

Group	Value	95% CI
Dolutegravir (>=14kg Cohort)	7
Standard of Care (>=14kg Cohort)	5
Dolutegravir (<14kg Cohort)	1
Standard of Care (<14kg Cohort)	1
Dolutegravir - ODYSSEY A (>=14kg Cohort)	5
Standard of Care - ODYSSEY A (>=14kg Cohort)	5
Dolutegravir - ODYSSEY B (>=14kg Cohort)	2
Standard of Care - ODYSSEY B (>=14kg Cohort)	0

Death

Group	Value	95% CI
Dolutegravir (>=14kg Cohort)	0
Standard of Care (>=14kg Cohort)	2
Dolutegravir (<14kg Cohort)	2
Standard of Care (<14kg Cohort)	4
Dolutegravir - ODYSSEY A (>=14kg Cohort)	0
Standard of Care - ODYSSEY A (>=14kg Cohort)	1
Dolutegravir - ODYSSEY B (>=14kg Cohort)	0
Standard of Care - ODYSSEY B (>=14kg Cohort)	1

HIV-1 RNA <50c/ml at 96 Weeks Secondary · 96 weeks post randomisation

Proportion of children with viral load suppression \<50 c/ml at 96 weeks.

Group	Value	95% CI
Dolutegravir (>=14kg Cohort)	270
Standard of Care (>=14kg Cohort)	252
Dolutegravir (<14kg Cohort)	27
Standard of Care (<14kg Cohort)	19
Dolutegravir - ODYSSEY A (>=14kg Cohort)	117
Standard of Care - ODYSSEY A (>=14kg Cohort)	113
Dolutegravir - ODYSSEY B (>=14kg Cohort)	153
Standard of Care - ODYSSEY B (>=14kg Cohort)	139

HIV-1 RNA <400c/mL at 96 Weeks Secondary · 96 weeks post randomisation

Proportion of children with viral load suppression \<400 c/ml at 96 weeks

Group	Value	95% CI
Dolutegravir (>=14kg Cohort)	299
Standard of Care (>=14kg Cohort)	285
Dolutegravir (<14kg Cohort)	33
Standard of Care (<14kg Cohort)	26
Dolutegravir - ODYSSEY A (>=14kg Cohort)	129
Standard of Care - ODYSSEY A (>=14kg Cohort)	124
Dolutegravir - ODYSSEY B (>=14kg Cohort)	170
Standard of Care - ODYSSEY B (>=14kg Cohort)	161

Mean Change in CD4 Count From Baseline to Week 96 Secondary · 96 weeks post randomisation

Reporting mean change from the global baseline value across both arms.

Group	Value	95% CI
Dolutegravir (>=14kg Cohort)	265	± 17
Standard of Care (>=14kg Cohort)	230	± 17
Dolutegravir (<14kg Cohort)	72	± 116
Standard of Care (<14kg Cohort)	51	± 118
Dolutegravir - ODYSSEY A (>=14kg Cohort)	311	± 23
Standard of Care - ODYSSEY A (>=14kg Cohort)	267	± 24
Dolutegravir - ODYSSEY B (>=14kg Cohort)	228	± 24
Standard of Care - ODYSSEY B (>=14kg Cohort)	202	± 24

Mean Change in Total Cholesterol From Baseline to Week 96 Secondary · 96 weeks post randomisation

Reporting mean change from global baseline value across both arms.

Group	Value	95% CI
Dolutegravir (>=14kg Cohort)	-5.0	± 1.5
Standard of Care (>=14kg Cohort)	9.9	± 1.5
Dolutegravir (<14kg Cohort)	4.5	± 5.6
Standard of Care (<14kg Cohort)	29.6	± 5.9
Dolutegravir - ODYSSEY A (>=14kg Cohort)	2.1	± 2.3
Standard of Care - ODYSSEY A (>=14kg Cohort)	19.6	± 2.3
Dolutegravir - ODYSSEY B (>=14kg Cohort)	-10.5	± 1.8
Standard of Care - ODYSSEY B (>=14kg Cohort)	2.8	± 1.8

Serious Adverse Events Secondary · Randomised phase: follow-up was censored when the last participant reached 96 weeks of follow-up (142 weeks (IQR:124 to 159) in ≥14kg cohort and 124 weeks (112 to 137) in <14kg cohort).

Incidence of serious adverse events

Group	Value	95% CI
Dolutegravir (>=14kg Cohort)	35
Standard of Care (>=14kg Cohort)	40
Dolutegravir (<14kg Cohort)	11
Standard of Care (<14kg Cohort)	11
Dolutegravir - ODYSSEY A (>=14kg Cohort)	23
Standard of Care - ODYSSEY A (>=14kg Cohort)	27
Dolutegravir - ODYSSEY B (>=14kg Cohort)	12
Standard of Care - ODYSSEY B (>=14kg Cohort)	13

Grade 3 or Above Clinical and Laboratory Adverse Events Secondary · Randomised phase: follow-up was censored when the last participant reached 96 weeks of follow-up (142 weeks (IQR:124 to 159) in ≥14kg cohort and 124 weeks (112 to 137) in <14kg cohort).

Incidence of new clinical and laboratory grade 3 and 4 adverse events

Group	Value	95% CI
Dolutegravir (>=14kg Cohort)	73
Standard of Care (>=14kg Cohort)	86
Dolutegravir (<14kg Cohort)	19
Standard of Care (<14kg Cohort)	21
Dolutegravir - ODYSSEY A (>=14kg Cohort)	48
Standard of Care - ODYSSEY A (>=14kg Cohort)	43
Dolutegravir - ODYSSEY B (>=14kg Cohort)	25
Standard of Care - ODYSSEY B (>=14kg Cohort)	43

Adverse Events Leading to ART Modification Any Grade Secondary · Randomised Phase

Incidence of adverse events (of any grade) leading to treatment modification

Group	Value	95% CI
Dolutegravir (>=14kg Cohort)	5
Standard of Care (>=14kg Cohort)	17
Dolutegravir (<14kg Cohort)	0
Standard of Care (<14kg Cohort)	2
Dolutegravir - ODYSSEY A (>=14kg Cohort)	3
Standard of Care - ODYSSEY A (>=14kg Cohort)	8
Dolutegravir - ODYSSEY B (>=14kg Cohort)	2
Standard of Care - ODYSSEY B (>=14kg Cohort)	9

Treatment Failure by 48 Weeks Secondary · 48 weeks post randomisation

Treatment failure by 48 weeks. Difference in proportion with clinical or virological failure (as defined above)

Insufficient virologic response

Group	Value	95% CI
Dolutegravir (>=14kg Cohort)	0
Standard of Care (>=14kg Cohort)	3
Dolutegravir (<14kg Cohort)	0
Standard of Care (<14kg Cohort)	0
Dolutegravir - ODYSSEY A (>=14kg Cohort)	0
Standard of Care - ODYSSEY A (>=14kg Cohort)	2
Dolutegravir - ODYSSEY B (>=14kg Cohort)	0
Standard of Care - ODYSSEY B (>=14kg Cohort)	1

Confirmed viral load >400c/ml

Group	Value	95% CI
Dolutegravir (>=14kg Cohort)	13
Standard of Care (>=14kg Cohort)	31
Dolutegravir (<14kg Cohort)	4
Standard of Care (<14kg Cohort)	11
Dolutegravir - ODYSSEY A (>=14kg Cohort)	4
Standard of Care - ODYSSEY A (>=14kg Cohort)	12
Dolutegravir - ODYSSEY B (>=14kg Cohort)	9
Standard of Care - ODYSSEY B (>=14kg Cohort)	19

Severe WHO stage 3

Group	Value	95% CI
Dolutegravir (>=14kg Cohort)	0
Standard of Care (>=14kg Cohort)	1
Dolutegravir (<14kg Cohort)	0
Standard of Care (<14kg Cohort)	0
Dolutegravir - ODYSSEY A (>=14kg Cohort)	0
Standard of Care - ODYSSEY A (>=14kg Cohort)	0
Dolutegravir - ODYSSEY B (>=14kg Cohort)	0
Standard of Care - ODYSSEY B (>=14kg Cohort)	1

WHO stage 4

Group	Value	95% CI
Dolutegravir (>=14kg Cohort)	7
Standard of Care (>=14kg Cohort)	5
Dolutegravir (<14kg Cohort)	1
Standard of Care (<14kg Cohort)	1
Dolutegravir - ODYSSEY A (>=14kg Cohort)	5
Standard of Care - ODYSSEY A (>=14kg Cohort)	5
Dolutegravir - ODYSSEY B (>=14kg Cohort)	2
Standard of Care - ODYSSEY B (>=14kg Cohort)	0

Death

Group	Value	95% CI
Dolutegravir (>=14kg Cohort)	0
Standard of Care (>=14kg Cohort)	2
Dolutegravir (<14kg Cohort)	2
Standard of Care (<14kg Cohort)	3
Dolutegravir - ODYSSEY A (>=14kg Cohort)	0
Standard of Care - ODYSSEY A (>=14kg Cohort)	1
Dolutegravir - ODYSSEY B (>=14kg Cohort)	0
Standard of Care - ODYSSEY B (>=14kg Cohort)	1

Treatment Failure by 144 Weeks Secondary · 144 weeks post randomisation

Treatment failure by 144 weeks. Difference in proportion with clinical or virological failure (as defined above)

Insufficient virologic response

Group	Value	95% CI
Dolutegravir (>=14kg Cohort)	0
Standard of Care (>=14kg Cohort)	3
Dolutegravir - ODYSSEY A (>=14kg Cohort)	0
Standard of Care - ODYSSEY A (>=14kg Cohort)	2
Dolutegravir - ODYSSEY B (>=14kg Cohort)	0
Standard of Care - ODYSSEY B (>=14kg Cohort)	1

Confirmed viral load>400c/mL

Group	Value	95% CI
Dolutegravir (>=14kg Cohort)	48
Standard of Care (>=14kg Cohort)	76
Dolutegravir - ODYSSEY A (>=14kg Cohort)	13
Standard of Care - ODYSSEY A (>=14kg Cohort)	28
Dolutegravir - ODYSSEY B (>=14kg Cohort)	35
Standard of Care - ODYSSEY B (>=14kg Cohort)	48

Severe WHO stage 3

Group	Value	95% CI
Dolutegravir (>=14kg Cohort)	0
Standard of Care (>=14kg Cohort)	1
Dolutegravir - ODYSSEY A (>=14kg Cohort)	0
Standard of Care - ODYSSEY A (>=14kg Cohort)	0
Dolutegravir - ODYSSEY B (>=14kg Cohort)	0
Standard of Care - ODYSSEY B (>=14kg Cohort)	1

WHO stage 4

Group	Value	95% CI
Dolutegravir (>=14kg Cohort)	8
Standard of Care (>=14kg Cohort)	5
Dolutegravir - ODYSSEY A (>=14kg Cohort)	6
Standard of Care - ODYSSEY A (>=14kg Cohort)	5
Dolutegravir - ODYSSEY B (>=14kg Cohort)	2
Standard of Care - ODYSSEY B (>=14kg Cohort)	0

Death

Group	Value	95% CI
Dolutegravir (>=14kg Cohort)	0
Standard of Care (>=14kg Cohort)	2
Dolutegravir - ODYSSEY A (>=14kg Cohort)	0
Standard of Care - ODYSSEY A (>=14kg Cohort)	1
Dolutegravir - ODYSSEY B (>=14kg Cohort)	0
Standard of Care - ODYSSEY B (>=14kg Cohort)	1

WHO 4, Severe WHO 3 Events and Death Secondary · Randomised phase: follow-up was censored when the last participant reached 96 weeks of follow-up (142 weeks (IQR:124 to 159) in ≥14kg cohort and 124 weeks (112 to 137) in <14kg cohort).

Rate of clinical events : WHO 4, severe WHO 3 events and death

Group	Value	95% CI
Dolutegravir (>=14kg Cohort)	8
Standard of Care (>=14kg Cohort)	8
Dolutegravir (<14kg Cohort)	3
Standard of Care (<14kg Cohort)	6
Dolutegravir - ODYSSEY A (>=14kg Cohort)	6
Standard of Care - ODYSSEY A (>=14kg Cohort)	6
Dolutegravir - ODYSSEY B (>=14kg Cohort)	2
Standard of Care - ODYSSEY B (>=14kg Cohort)	2

Per Protocol: Treatment Failure by 96 Weeks Secondary · 96 weeks post randomisation

Per protocol: treatment failure by 96 weeks post randomisation

Group	Value	95% CI
Dolutegravir (>=14kg Cohort)	44
Standard of Care (>=14kg Cohort)	62
Dolutegravir (<14kg Cohort)	12
Standard of Care (<14kg Cohort)	20
Dolutegravir - ODYSSEY A (>=14kg Cohort)	13
Standard of Care - ODYSSEY A (>=14kg Cohort)	28
Dolutegravir - ODYSSEY B (>=14kg Cohort)	31
Standard of Care - ODYSSEY B (>=14kg Cohort)	34

Adverse events — posted to ClinicalTrials.gov

Time frame: Randomised phase: follow-up was censored when the last participant reached 96 weeks of follow-up (142 weeks (IQR:124 to 159) in ≥14kg cohort and 124 weeks (112 to 137) in <14kg cohort).. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Dolutegravir (>=14kg Cohort)

Serious: 35/350 (10%)

Deaths: 2/350

Standard of Care (>=14kg Cohort)

Serious: 40/357 (11%)

Deaths: 3/357

Dolutegravir (<14kg Cohort)

Serious: 11/42 (26%)

Deaths: 2/42

Standard of Care (<14kg Cohort)

Serious: 11/43 (26%)

Deaths: 4/43

Dolutegravir - ODYSSEY A (>=14kg Cohort)

Serious: 23/154 (15%)

Deaths: 2/154

Standard of Care - ODYSSEY A (>=14kg Cohort)

Serious: 27/157 (17%)

Deaths: 2/157

Dolutegravir - ODYSSEY B (>=14kg Cohort)

Serious: 12/196 (6%)

Deaths: 0/196

Standard of Care - ODYSSEY B (>=14kg Cohort)

Serious: 13/200 (7%)

Deaths: 1/200

Serious adverse events (19 terms)

Reaction	System	Dolutegravir (>=14kg Cohort)	Standard of Care (>=14kg C…	Dolutegravir (<14kg Cohort)	Standard of Care (<14kg Co…	Dolutegravir - ODYSSEY A (…	Standard of Care - ODYSSEY…	Dolutegravir - ODYSSEY B (…	Standard of Care - ODYSSEY…
Infections and infestations	Infections and infestations	—	—	—	—	—	—	—	—
Nervous system disorders	Nervous system disorders	—	—	—	—	—	—	—	—
Blood and lymphatic system disorders	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—	—	—
Psychiatric disorders	Psychiatric disorders	—	—	—	—	—	—	—	—
Injury, poisoning and procedural complications	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—
Investigations	Investigations	—	—	—	—	—	—	—	—
Renal and urinary disorders	Renal and urinary disorders	—	—	—	—	—	—	—	—
Skin and subcutaneous tissue disorders	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—
Musculoskeletal and connective tissue disorders	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—
Metabolism and nutrition disorders	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—
Vascular disorders	Vascular disorders	—	—	—	—	—	—	—	—
Immune system disorders	Immune system disorders	—	—	—	—	—	—	—	—
Pregnancy, puerperium and perinatal conditions	Pregnancy, puerperium and perinatal conditions	—	—	—	—	—	—	—	—
General disorders and administration site conditions	General disorders	—	—	—	—	—	—	—	—
Cardiac disorders	Cardiac disorders	—	—	—	—	—	—	—	—
Respiratory, thoracic and mediastinal disorders	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—
Gastrointestinal disorders	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Hepatobiliary disorders	Hepatobiliary disorders	—	—	—	—	—	—	—	—

Most-reported serious reactions: Infections and infestations, Nervous system disorders, Blood and lymphatic system disorders, Neoplasms benign, malignant and unspecified (incl cysts and polyps), Psychiatric disorders, Injury, poisoning and procedural complications, Investigations, Renal and urinary disorders.

Data from ClinicalTrials.gov NCT02259127 adverse events section.

Sponsor's own description

A new anti-HIV medicine (Dolutegravir) combined with 2 currently used anti-HIV medicines is non-inferior to the standard combination of medicines used in terms of efficacy and better in terms of toxicity.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
Turkova A, White E, Mujuru HA, Kekitiinwa AR, et al · · 2021 · cited 106× · PMID 34965338 · DOI 10.1056/nejmoa2108793
Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.
Bollen PDJ, Moore CL, Mujuru HA, Makumbi S, et al · · 2020 · cited 38× · PMID 32763217 · DOI 10.1016/s2352-3018(20)30189-2
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
Moore CL, Turkova A, Mujuru H, Kekitiinwa A, et al · · 2021 · cited 34× · PMID 33446115 · DOI 10.1186/s12879-020-05672-6
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial.
Ruel TD, Acosta EP, Liu JP, Gray KP, et al · · 2022 · cited 33× · PMID 35489377 · DOI 10.1016/s2352-3018(22)00044-3
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
Waalewijn H, Chan MK, Bollen PDJ, Mujuru HA, et al · · 2022 · cited 31× · PMID 35189082 · DOI 10.1016/s2352-3018(21)00292-7
"Because we all have to grow up": supporting adolescents in Uganda to develop core competencies to transition towards managing their HIV more independently.
Lanyon C, Seeley J, Namukwaya S, Musiime V, et al · · 2020 · cited 30× · PMID 32869514 · DOI 10.1002/jia2.25552
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial.
Amuge P, Lugemwa A, Wynne B, Mujuru HA, et al · · 2022 · cited 24× · PMID 36055295 · DOI 10.1016/s2352-3018(22)00163-1
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
Turkova A, Waalewijn H, Chan MK, Bollen PDJ, et al · · 2022 · cited 21× · PMID 35868341 · DOI 10.1016/s2352-3018(22)00160-6

Verify or expand the search:

Other trials of Dolutegravir

Trials testing the same drug.

NCT07124559 — A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of · Phase 1, PHASE2 · not yet recruiting
NCT07532304 — A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Parti · Phase 1 · not yet recruiting
NCT05652478 — Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study · Phase 2 · recruiting
NCT06805656 — Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals · Phase 2 · not yet recruiting
NCT05979311 — A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Ora · Phase 3 · active not recruiting

Other recruiting trials for HIV Infection

Currently open trials in the same condition.

NCT06900829 — #AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-i · NA · recruiting
NCT06908252 — MAPS PrEP Van Study · Phase 4 · recruiting
NCT07042945 — MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003) · Phase 1 · recruiting
NCT06716450 — Multiplo Tp/HIV Self-Test · NA · recruiting
NCT07086989 — Cardiovascular Risk in Children With Chronic Conditions Study · recruiting

Other PENTA Foundation trials

Trials by the same sponsor.

NCT06482151 — Evaluation of the Prevalence of E. Coli O Serotypes in Paediatric Population With Recurrent Urinary Tract Infection · withdrawn
NCT06139796 — Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV · Phase 1, PHASE2 · withdrawn
NCT05993767 — UNIVERSAL 1: Pharmacokinetic Study of a Novel DTG/FTC/TAF Dose Ratio for Children · Phase 2 · completed
NCT05947786 — Mpox Paediatric and Adolescent Clinical Study · unknown
NCT04337450 — DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to · Phase 2, PHASE3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02259127 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by PENTA Foundation
Last refreshed: 29 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02259127.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT02259127

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (19 terms)

Sponsor's own description

Publications & conference data

Related trials

Other trials of Dolutegravir

Other recruiting trials for HIV Infection

Other PENTA Foundation trials

Verify against primary sources